Sector
PharmaceuticalsOpen
₹1,837.1Prev. Close
₹1,834.2Turnover(Lac.)
₹1,257.23Day's High
₹1,837.15Day's Low
₹1,80452 Week's High
₹2,220.9552 Week's Low
₹1,585.7Book Value
₹576.62Face Value
₹1Mkt Cap (₹ Cr.)
29,873.61P/E
27.38EPS
66.94Divi. Yield
1.09Gland Pharma stock has gained a total of 12% in the last one year, and 7.37% dip since the beginning of the year.
Here are some of the stocks that may see significant price movement today: Tata Power, Chambal Fertilisers, Cummins India, etc.
The inspection concluded with three 483 observations. Gland Pharma clarified that these observations are procedural and not related to data integrity or repeat issues.
Y/e 31 Mar( In .Cr) | Mar-2024 | Mar-2023 | Mar-2022 | Mar-2021 |
---|---|---|---|---|
Equity Capital | 16.47 | 16.47 | 16.51 | 16.36 |
Preference Capital | 0 | 0 | 0 | 0 |
Reserves | 8,978.82 | 7,936.83 | 7,141.72 | 5,886.93 |
Net Worth | 8,995.29 | 7,953.3 | 7,158.23 | 5,903.29 |
Minority Interest |
Y/e 31 Mar( In .Cr) | Mar-2022 | Mar-2021 | Mar-2017 |
---|---|---|---|
Revenue | 4,400.7 | 3,462.87 | 1,479.17 |
yoy growth (%) | 27.08 | 134.1 | |
Raw materials | -2,109.21 | -1,491.87 | -509.73 |
As % of sales | 47.92 | 43.08 | 34.46 |
Employee costs | -338.56 | -311.36 | -153.41 |
Y/e 31 Mar( In .Cr) | Mar-2022 | Mar-2021 | Mar-2017 |
---|---|---|---|
Profit before tax | 1,619.04 | 1,334.85 | 578.01 |
Depreciation | -110.29 | -98.78 | -74.14 |
Tax paid | -406.88 | -337.84 | -164.28 |
Working capital | 496.99 | 3,455.68 | |
Other operating items |
Y/e 31 Mar | Mar-2022 | Mar-2021 | Mar-2017 |
---|---|---|---|
Growth matrix (%) | |||
Revenue growth | 27.08 | 134.1 | |
Op profit growth | 16 | 108.36 | |
EBIT growth | 21.37 | 128.99 | |
Net profit growth | 21.57 | 140.98 |
Particulars (Rupees in Crores.) | Mar-2024 | Mar-2023 | Mar-2022 | Mar-2021 | Mar-2020 |
---|---|---|---|---|---|
Gross Sales | 5,664.72 | 3,624.6 | 4,400.71 | 3,462.88 | 2,633.24 |
Excise Duty | 0 | 0 | 0 | 0 | 0 |
Net Sales | 5,664.72 | 3,624.6 | 4,400.71 | 3,462.88 | 2,633.24 |
Other Operating Income | 0 | 0 | 0 | 0 | 0 |
Other Income | 170.24 | 240.46 | 223.94 | 134.78 | 139.17 |
Company Name | LTP (₹) | P/E (%) | Mkt.Cap (₹Cr.) | NP Qtr (₹Cr.) | Div.Yield (%) | Sales Qtr (₹.Cr) | Book Value (₹) |
---|---|---|---|---|---|---|---|
Sun Pharmaceuticals Industries Ltd SUNPHARMA | 1,813.45 | 157.5 | 4,34,195.65 | 863.29 | 0.75 | 5,123.67 | 98.33 |
Divis Laboratories Ltd DIVISLAB | 6,096.2 | 88.09 | 1,61,829.65 | 518 | 0.49 | 2,302 | 513.62 |
Cipla Ltd CIPLA | 1,498.25 | 28.59 | 1,21,053.04 | 1,178.16 | 0.87 | 3,969.86 | 360.73 |
Torrent Pharmaceuticals Ltd TORNTPHARM | 3,361.5 | 69.57 | 1,13,812.4 | 460 | 0.83 | 2,376 | 222.38 |
Mankind Pharma Ltd MANKIND | 2,615.5 | 52.35 | 1,04,937.42 | 634.43 | 0 | 2,529.74 | 269.23 |
Figures of Market Capital(Mar Cap), Quarterly Net Profit(NP Qtr) and Quarterly Sales(Sales Qtr) are in ₹ Cr.
Chairman & Independent Directo
Yiu Kwan Stanley Lau
Managing Director & CEO
SRINIVAS SADU
Non-Exec & Non-Independent Dir
UDO JAHANNES VETTER
Independent Director
C S N Murthy
Independent Director
ESSAJI GOOLAM VAHANVATI
Independent Director
Naina Lal Kidwai
Non-Exec & Non-Independent Dir
Jia Ai (Allen) Zhang
Non Executive Director
Wenjie Zhang
Additional Director
Wei Huang
Tel: -
Website: -
Email: -
Tel: -
Website: -
Email: -
Reports by Gland Pharma Ltd
Summary
Gland Pharma Ltd was incorporated as Gland Pharma Private Limited, a private limited company under the Companies Act, 1956 on March 20, 1978 and was granted the certificate of incorporation by Registrar of Companies, Andhra Pradesh at Hyderabad. Subsequently, the name of the Company was changed to Gland Pharma Limited pursuant to a special resolution passed by the shareholders of the Company on December 5, 1994 and a fresh certificate of incorporation dated April 25, 1995 was issued by the Registrar of Companies, Andhra Pradesh at Hyderabad consequent upon change of name and conversion into a public limited company under the Companies Act, 1956. The Company is primarily engaged in manufacturing injectable formulations.The company is one of the fastest growing generic injectables-focused companies by revenue in the United States from 2014 to 2019. The company has 8 manufacturing facilities in India, comprising four finished formulations facilities with a total of 23 production lines and three API facilities. The company sells products primarily under a business to business (B2B) model in over 60 countries as of March 31, 2022, including the United States, Europe, Canada, Australia, India and the Rest of the world. The company has a consistent compliance track record with a range of regulatory regimes across these markets. The company also have an extensive track record in complex injectables development, manufacturing and marketing and a close understanding of the related soph
Read More
The Gland Pharma Ltd shares price on NATIONAL STOCK EXCHANGE (NSE) is ₹1813.25 today.
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Gland Pharma Ltd is ₹29873.61 Cr. as of 06 Dec ‘24
The PE and PB ratios of Gland Pharma Ltd is 27.38 and 3.29 as of 06 Dec ‘24
The 52-week high/low is the highest and lowest price at which a Gland Pharma Ltd stock has traded during that given time period (similar to 1 year) and is considered as a technical indicator. The 52 week high and low of Gland Pharma Ltd is ₹1585.7 and ₹2220.95 as of 06 Dec ‘24
Gland Pharma Ltd's CAGR for 5 Years at 0.16%, 3 Years at -19.84%, 1 Year at 1.29%, 6 Month at 0.06%, 3 Month at -3.04% and 1 Month at 0.07%.
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
IIFL Securities Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
Invest wise with Expert advice